Topic
What GLP-1 drugs are coming next?
Retatrutide, CagriSema, MariTide and every GLP-1 drug in development.
CagriSema: What to Know While It Sits at the FDACagriSema is Novo Nordisk's combination of semaglutide and the amylin drug cagrilintide. It has been under FDA review since December 2025. Here is what the REDEFINE trials found, why the head-to-head against Zepbound mattered, and what a decision would actually mean for you.Every GLP-1 Drug in Development in 2026: The Full Pipeline, ExplainedA plain-English guide to the obesity and GLP-1 drugs now in development, which companies are behind them, how far along they are, and what each one is actually trying to do differently.Every GLP-1 Drug in Development, Ranked by How Close It Is to ApprovalMore than 25 weight-loss drugs are in late-stage development. This ranks them by one thing only: how close each is to an FDA decision, based on filing status and clinical trial registry dates as of September 14, 2026. One is under review right now. Most will not reach a pharmacy before 2029.How to Join a GLP-1 Clinical Trial: A Step-by-Step GuideAbout 529 interventional obesity studies were recruiting in the United States as of September 14, 2026. A trial is the only legal way to take an investigational drug like retatrutide or MariTide. Here is exactly how to find one, what you will be asked, what it costs, what your rights are, and which big trials were open.Lilly vs. Novo Nordisk: The Obesity Drug War, ExplainedHow Eli Lilly overtook Novo Nordisk in the US weight-loss market, where Novo is still winning, and what the rivalry means for what you pay and what you can get.MariTide: What to Know About the Monthly Weight-Loss ShotAmgen's MariTide is designed to be injected once a month, and possibly as few as four to six times a year. Here is what the trials have shown, when Phase 3 data are due, why it blocks the GIP receptor instead of activating it, and how to join one of the large studies still enrolling.Mazdutide: What to Know About the GLP-1 Drug Approved in China but Not the USMazdutide is a real, approved, prescribed weight-loss drug, just not in the United States. Here is what it is, what the GLORY trials showed, why Eli Lilly holds the US rights but has not filed, and why anything sold to Americans as mazdutide is not the approved Chinese medicine.Orforglipron (Foundayo): The GLP-1 Pill, ExplainedWhat orforglipron is, how much weight people lost in the trials, what it costs, and how it differs from the Wegovy pill and from injections like Wegovy and Zepbound.Retatrutide: What to Know About the Triple AgonistRetatrutide produced the biggest weight-loss numbers ever reported in a Phase 3 obesity trial, but it is not approved, not available, and comes with side effects worth understanding before the hype.Retatrutide: What to Know and When You Could Actually Get ItRetatrutide produced the largest average weight loss ever reported in a pivotal obesity trial, but it is still investigational. Here is where it stands, what the numbers really say, when Eli Lilly plans to file with the FDA, and how people are getting access legally today.Survodutide: What to Know About Boehringer's Glucagon Weight-Loss DrugSurvodutide lost less weight than retatrutide or tirzepatide in its pivotal trial, but it cut liver fat by about 63% and visceral fat by about 34%. Here is what the SYNCHRONIZE trials actually showed, why the FDA gave it breakthrough status for liver disease, when it might be filed, and which survodutide trials are still open.VK2735: What to Know About Viking's Weight-Loss Shot and PillVK2735 is the only GLP-1/GIP drug being developed as both a weekly injection and a daily pill with the same active ingredient. Here is what the Phase 2 trials showed, where the VANQUISH Phase 3 trials stand, when data are expected, and why nothing sold online as VK2735 is the real thing.When Will Generic Ozempic Be Available in the US?Generic semaglutide is already on sale in India and Canada, but the US patent situation pushes an American generic to the end of 2031 at the earliest. Here is the timeline and what is available in the meantime.Zenagamtide (Amycretin): What to Know About Novo's Next Big BetZenagamtide is the drug formerly called amycretin: one molecule that hits both the GLP-1 and amylin receptors, in development as a weekly shot and a daily pill. Here is what the early results showed, where the Phase 3 AMAZE and AMBITION trials stand, which ones are recruiting, and what the realistic timeline looks like.